Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Talazoparib plus enzalutamide showed improved radiographic progression-free survival (rPFS) compared to placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
The most common treatment-emergent adverse events observed in the talazoparib group were anaemia, neutropenia, and fatigue, with anaemia being the most common grade 3-4 event.

Image courtesy of interviewee. November 11, 2023

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © Faculti Media Limited 2013 - 2024. All rights reserved.
error: